TL;DR:
- Orbem, a German deep-tech firm, secures €30 million in Series A funding to advance AI-driven MRI technology applications.
- AI-powered MRI tech is utilized in food, construction, and medical sectors, addressing various challenges.
- Notable applications include in-ovo sexing for ethical poultry farming and assessing crop viability.
- Funding round was led by 83North, with participation from prominent investors and German entrepreneurs.
- CEO Dr. Pedro Gómez emphasizes Orbem’s mission to use AI-powered imaging to address global challenges.
Main AI News:
In a groundbreaking stride towards revolutionizing imaging technology, German deep-tech company Orbem has successfully harnessed the power of artificial intelligence (AI) in conjunction with MRI technology. This innovative approach has opened doors to a myriad of applications across diverse industries, including food, construction, and healthcare. One notable application involves the non-invasive scanning of biological samples, such as eggs, a technique that has gained prominence due to its role in addressing ethical concerns.
The European Union’s move to ban the culling of male-day-old chicks has put significant pressure on the agricultural sector to explore alternative methods. Orbem’s in-ovo sexing technology not only ensures compliance with these regulations but also represents a pivotal step towards ethical and sustainable poultry farming practices.
Moreover, this cutting-edge technology finds utility beyond the realm of agriculture. In the agricultural sector, it serves as a valuable tool for assessing the viability of crop growth. Meanwhile, in the construction industry, it contributes to the critical task of evaluating the structural integrity of biodegradable materials.
Orbem’s journey towards innovation has recently received a substantial boost, with the successful completion of a €30 million Series A funding round. This funding endeavor was spearheaded by 83North, a leading venture capital firm, and saw participation from a constellation of prominent investors. The Venture Collective, Possible Ventures, Dr. Rüdiger Schmidt, and a new addition to the roster, La Famiglia, joined forces to support Orbem’s ambitious mission.
Notably, the round also garnered interest and investment from some of Germany’s most influential entrepreneurs, including Hanno Renner, Roman Schumacher, Jonas Rieke, Rubin Ritter, Michael Wax, Erik Muttersbach, Dr. Michael Ardelt, Dr. Alexander Hüttenbrink, Dr. Oliver Trinchera, and Bastian Nominacher. This diverse lineup of backers underscores the widespread recognition of Orbem’s potential to reshape industries.
Dr. Pedro Gómez, co-founder and CEO of Orbem, articulated the company’s vision: “Our mission is to unleash AI-powered imaging for everything and everyone. We believe this is the best way to carry out our core purpose of shedding light on the world’s toughest challenges. With €30 million in funding, we will have the utmost flexibility to realize our vision of deploying AI-powered imaging to sustainably address global food security, accelerate the transition to a green economy, and transform disease detection.”
The confluence of digitization, technological innovation, and the AI revolution has created a golden opportunity for companies to address real-world challenges while building robust, independent businesses. Gil Goren, General Partner at 83North, expressed enthusiasm about joining Orbem on their journey towards a brighter future, stating, “Orbem has harnessed AI to industrialize MRI technology, unlocking the potential to revolutionize food production, expedite the transition toward a sustainable economy, and enhance disease detection. It is a great pleasure joining this amazing crew on a journey to a better world.”
Conclusion:
Orbem’s successful €30 million funding round and its innovative application of AI-enhanced MRI technology signify a significant advancement in imaging across various industries. Their commitment to ethical and sustainable practices in agriculture and the potential to revolutionize food production and disease detection highlight their pivotal role in shaping the market’s future. This funding positions Orbem to further deploy AI-powered imaging, driving positive change and addressing critical challenges.
